Thursday, June 24, 2021 Daily Archives

The Path Toward Successful Innovation in Gene Therapies

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Roland W. Herzog, PhD, Professor of Pediatrics, Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program, Indiana University School of Medicine, and Nagendra Venkata Chemuturi, PhD, Scientific Director Research, Global DMPK, Takeda Pharmaceutical Company Gene therapies based on adenoassociated virus (AAV) vectors are emerging as a promising treatment strategy for various diseases, including an inherited form of blindness and spinal muscular atrophy. A major obstacle for the wide use of gene…

$250m CAR-T startup ‘validates’ Intellia’s allogeneic and CRISPR platforms

Intellia Therapeutics, Blackstone, and Cellex have launched a CAR-T biotech aimed at developing chimeric antigen receptor (CAR) T-cell therapies. The new company will combine Intellia’s allogeneic cell platform and CRISPR cell engineering with Cellex subsidiary GEMoaB’s switchable universal CAR-T platforms – UniCAR and RevCAR – to develop a range of therapies against various cancers, including solid tumors. Blackstone Life Sciences has invested $250 million in the new venture, and the three companies – Blackstone, Intellia, and Cellex – will each…

Inceptor Bio creates consortium to take on cancer

Inceptor Bio will collaborate with companies and academic institutions to develop multiple cell and gene therapy platforms to cure cancers. Inceptor Bio is creating the consortium to focus on specific technologies aimed at creating cures for various types of cancer. However, Inceptor did not disclose who the specific scientists, companies, and academic institutions they are working with are, but the project will be by its Advanced Manufacturing Platform (AMP+). The AMP+ cell and gene manufacturing site is being built at…

Lonza bags three deals in one week

Lonza will develop an immunotherapeutic drug candidate for SelectImmune, an antibody for ValenzaBio and extends its collaboration with Pinteon. All in a week’s work for the Swiss CDMO. SelectImmune Pharma has collaborated with Swiss contract development manufacturing organization (CDMO) Lonza to develop processes for a novel immunotherapy protein drug (NIpD). “SelectImmune is developing NlpD, an anti-infectious and anti-inflammatory protein that is released by beneficial bacteria in our gut,” Yvette Stallwood, head of Applied Protein Services at Lonza told us. “This…